The success rate of drug development programs is improved by biomarkers and the availability of new therapeutics is thereby accelerated. The production of biomarkers is a multi-step and iterative process that starts with the discovery of biomarkers in samples of diseases and nondiseases. A biomarker could be used as a proxy for a natural outcome. such as survival or permanent morbidity, in assessing possible drug therapies. If the biomarker, which has a direct correlation to better health, is altered by a medication, the biomarker acts as a surrogate endpoint to determine clinical gain.
Lakshmi Deeraja Manvi Gatta